Table 6.
Univariate analysis of SGRQ-improved versus non-improved participants with airway obstruction defined by FEV1/FVC<0.7
| Improved (n=31) | Non-improved (n=45) | p Value | |
|---|---|---|---|
| Male sex | 21 (67.7) | 34 (75.6) | 0.456 |
| Age, year | 66.6±9.7 | 67.8±9.7 | 0.597 |
| Cigarettes smoked daily, N | 23.3±12.4 | 22.4±12.6 | 0.758 |
| Duration of smoking, year | 45.4±12.0 | 46.3±11.5 | 0.733 |
| Brinkman Index | 1072.7±675.9 | 994.0±525.8 | 0.570 |
| TDS score | 8.0±1.5 | 7.2±1.7 | 0.040 |
| Baseline exhaled CO, ppm | 11.6±7.0 | 10.5±8.4 | 0.529 |
| Changes in exhaled CO, ppm | −8.6±7.9 | −5.0±7.0 | 0.041 |
| Body mass index, kg/m2 | 23.4±3.5 | 21.8±3.5 | 0.639 |
| Baseline FEV1, % predicted | 52.0±19.8 | 60.3±17.8 | 0.061 |
| Baseline FVC, % predicted | 73.6±21.5 | 81.5±17.4 | 0.085 |
| FEV1/FVC, % | 56.0±11.6 | 58.9±9.4 | 0.223 |
| Changes in FEV1, L | 0.13±0.28 | 0.08±0.32 | 0.513 |
| Treated by varenicline | 13 (41.9) | 20 (44.4) | 0.828 |
| Quitter | 17 (54.8) | 33 (73.3) | 0.096 |
| Mental disorder | 6 (19.4) | 10 (22.2) | 0.762 |
| Diabetes mellitus | 3 (9.7) | 5 (11.1) | 0.841 |
| Cardiovascular disease | 8 (25.8) | 6 (13.3) | 0.172 |
| COPD | 17 (54.8) | 16 (35.6) | 0.095 |
| Bronchial asthma | 6 (19.4) | 7 (15.6) | 0.667 |
| Cancer | 4 (12.9) | 6 (13.3) | 0.957 |
Data are presented as number (%) or mean±SD.
COPD, chronic obstructive pulmonary disease; FEV1, forced expiratory volume in 1 s; FVC, forced vital capacity; SGRQ, St. George's Respiratory Questionnaire; TDS, Tobacco Dependence Screener test.